136 related articles for article (PubMed ID: 33501733)
21. Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: The Petale study.
Petrykey K; Lippé S; Robaey P; Sultan S; Laniel J; Drouin S; Bertout L; Beaulieu P; St-Onge P; Boulet-Craig A; Rezgui A; Yasui Y; Sapkota Y; Krull KR; Hudson MM; Laverdière C; Sinnett D; Krajinovic M
PLoS One; 2019; 14(6):e0217314. PubMed ID: 31181069
[TBL] [Abstract][Full Text] [Related]
22. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia
.
Zang YN; Wang SZ; Qin Y; Zhang JR; Zhao LB; Wang XL
Int J Clin Pharmacol Ther; 2019 Aug; 57(8):402-407. PubMed ID: 31232278
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.
Liu SG; Gao C; Zhang RD; Zhao XX; Cui L; Li WJ; Chen ZP; Yue ZX; Zhang YY; Wu MY; Wang JX; Li ZG; Zheng HY
Oncotarget; 2017 Jun; 8(23):37761-37772. PubMed ID: 28525903
[TBL] [Abstract][Full Text] [Related]
26. CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.
Xue Y; Rong L; Tong N; Wang M; Zhang Z; Fang Y
Int J Clin Exp Pathol; 2015; 8(9):11594-600. PubMed ID: 26617896
[TBL] [Abstract][Full Text] [Related]
27. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.
Finkelstein Y; Blonquist TM; Vijayanathan V; Stevenson KE; Neuberg DS; Silverman LB; Vrooman LM; Sallan SE; Cole PD
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27957785
[TBL] [Abstract][Full Text] [Related]
28. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
30. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
31. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia.
Zobeck M; Bernhardt MB; Kamdar KY; Rabin KR; Lupo PJ; Scheurer ME
Pharmacotherapy; 2023 Mar; 43(3):205-214. PubMed ID: 36764694
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.
Imanishi H; Okamura N; Yagi M; Noro Y; Moriya Y; Nakamura T; Hayakawa A; Takeshima Y; Sakaeda T; Matsuo M; Okumura K
J Hum Genet; 2007; 52(2):166-171. PubMed ID: 17180579
[TBL] [Abstract][Full Text] [Related]
33. Study on Relationships of Tumor Status and Gene Polymorphism With Blood Concentration of MTX and Toxicities in 63 Pediatric Mature B Cell Lymphoma in Chinese Population.
Huang S; Jin L; Yang J; Duan LY; Zhang M; Zhou JC; Zhang HY
Technol Cancer Res Treat; 2021; 20():1533033821995288. PubMed ID: 33752528
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
35. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
[TBL] [Abstract][Full Text] [Related]
36. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
[TBL] [Abstract][Full Text] [Related]
37. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia.
Orgel E; Nabais T; Douglas C; Mittelman SD; Neely M
J Clin Pharmacol; 2021 Jun; 61(6):755-762. PubMed ID: 33314168
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
[TBL] [Abstract][Full Text] [Related]
39. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
40. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
